That was my thought after hearing a hospital can stock enough Leronlimab for 100 patients with only one CSP. The amount of paper work for one eIND here in the U.S. is enough to discourage a doctor from using it. This shows the level of confidence the Philippines FDA has with Leronlimab.
It’s quite revealing that the government in the phillipines is more responsive to the needs on its citizens and apparently less corrupt than the United States.
Market Data 
Markets 
AI
